Added to YB: 2025-04-23
Pitch date: 2025-04-20
NVO [bullish]
Novo Nordisk A/S
-21.77%
current return
Author Info
Capitalist Letters simplifies investing and makes it understandable for everybody. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 363.23
Price Target
118.00 (-58%)
Dividend
3.91%
EV/EBITDA
8.27
P/E
10.92
EV/Sales
4.43
Sector
Pharmaceuticals
Category
growth
Novo Nordisk: Easy Double From Here?
NVO: Dominant in diabetes/weight-loss drugs with superior pipeline vs Eli Lilly despite timing disadvantage. Weight-loss market to grow 5x by 2030 ($100B+). Rock-solid balance sheet with industry-leading margins (85% gross/30% ROIC). Phenomenal 20% 5yr earnings growth at bargain 14x forward P/E.
Read full article (13 min)